$MBOT

Microbot Medical Inc.

CIK:0000883975|SEC Filings

Interim Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Revenues	$ 241		$ 346
Cost of Revenues	(884)		(987)
Gross loss	(643)		(641)
Research and development, net	(1,861)	(2,111)	(3,154)	(3,570)
Sales, general and administrative	(3,684)	(1,612)	(6,713)	(3,174)
Operating loss	(6,188)	(3,723)	(10,508)	(6,744)
Other income (see Note 3F)				316
Financing income, net	561	223	1,210	327
Net loss	$ (5,627)	$ (3,500)	$ (9,298)	$ (6,101)
Basic net loss per share	$ (0.08)	$ (0.10)	$ (0.14)	$ (0.18)
Diluted net loss per share	$ (0.08)	$ (0.10)	$ (0.14)	$ (0.18)
Basic weighted average common shares outstanding	67,163,613	36,488,014	67,160,844	33,801,734
Diluted weighted average common shares outstanding	67,163,613	36,488,014	67,160,844	33,801,734

Interim Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Operating activities:
Net loss	$ (5,627)	$ (3,500)	$ (9,298)	$ (6,101)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation of property and equipment			27	27
Interest income and unrealized gains from marketable securities			(215)	(119)
Share-based compensation	433	237	655	493
Changes in assets and liabilities:
Accounts receivable			(176)
Inventory			(2,323)
Prepaid expenses and other assets			69	161
Other payables and accrued liabilities			1,219	92
Net cash flows used in operating activities			(10,042)	(5,447)
Investing activities:
Purchases of property and equipment			(250)	(22)
Purchases of marketable securities			(1,070)	(31,918)
Proceeds from sales of marketable securities			11,750	5,801
Increase in long-term deposit			(148)
Increase in restricted deposit			(814)
Net cash flows provided by (used in) investing activities			9,468	(26,139)
Financing activities:
Issuance of common stock and warrants, net			16	32,558
Net cash flows provided by financing activities			16	32,558
Increase (decrease) in cash, cash equivalents and restricted cash			(558)	972
Cash, cash equivalents and restricted cash at beginning of period			3,973	3,163
Cash, cash equivalents and restricted cash at end of period	3,415	4,135	3,415	4,135
Supplemental disclosure of non-cash investing and financing activities:
Right-of-use assets obtained in exchange for lease liabilities			101	89
Issuance costs not paid				93
Deferred issuance costs				30
Supplemental disclosure of cash flow information:
Cash and cash equivalents	3,152	4,082	3,152	4,082
Restricted cash	263	53	263	53
Cash, cash equivalents and restricted cash	$ 3,415	$ 4,135	$ 3,415	$ 4,135

Interim Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 3,152	$ 3,912
Marketable securities	64,215	74,680
Restricted cash	200	2
Restricted deposit	814
Accounts receivable	176
Inventory	2,907	584
Prepaid expenses and other current assets	709	644
Total current assets	72,173	79,822
Long-term assets:
Restricted cash	63	59
Long-term deposit	13	737
Property and equipment, net	316	93
Operating right-of-use assets	800	833
Total assets	73,365	81,544
Current liabilities:
Accounts payable	871	511
Lease liabilities	326	296
Accrued liabilities	2,691	2,614
Total current liabilities	3,888	3,421
Non-current liabilities:
Long-term lease liabilities	550	569
Total liabilities	4,438	3,990
Shareholders’ equity:
Common stock; $0.01 par value; 120,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 67,164,801 and 67,158,044 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively.	672	672
Additional paid-in capital	181,639	180,968
Accumulated deficit	(113,384)	(104,086)
Total shareholders’ equity	68,927	77,554
Total liabilities and shareholders’ equity	$ 73,365	$ 81,544